Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Selby

Showing results (261-270 of 316) with videos related to

Pageof 32
Sort By:
British Journal of Cancer|January 1, 1997
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokinesR E Banks, M A Forbes, S Hallam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2008
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancerP M Patel, S Sim, D O O'Donnell, et al.
Kidney International|June 7, 2013
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantationMatthew P Welberry Smith, Alexandre Zougman, David A Cairns, et al.
Molecular Human Reproduction|June 10, 1998
Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1R E Banks, M A Forbes, J Searles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Workgroup II: the screening process. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)S Winawer, J Faivre, J Selby, et al.
Plos One|September 10, 2016
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Plos One|November 19, 2016
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Cytokine|May 11, 2000
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effectsR E Banks, M A Forbes, P M Patel, et al.
British Journal of Haematology|March 22, 2001
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myelomaF E Davies, P D Forsyth, A C Rawstron, et al.
British Journal of Urology|May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activationJ K Joffe, R E Banks, M A Forbes, et al.
Pageof 32

Showing results (261-270 of 316) with videos related to

Sort By:
Pageof 32
British Journal of Cancer|January 1, 1997
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokinesR E Banks, M A Forbes, S Hallam, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2008
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancerP M Patel, S Sim, D O O'Donnell, et al.
Kidney International|June 7, 2013
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantationMatthew P Welberry Smith, Alexandre Zougman, David A Cairns, et al.
Molecular Human Reproduction|June 10, 1998
Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1R E Banks, M A Forbes, J Searles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Workgroup II: the screening process. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)S Winawer, J Faivre, J Selby, et al.
Plos One|September 10, 2016
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Plos One|November 19, 2016
Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyMark J Selby, John J Engelhardt, Robert J Johnston, et al.
Cytokine|May 11, 2000
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effectsR E Banks, M A Forbes, P M Patel, et al.
British Journal of Haematology|March 22, 2001
The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myelomaF E Davies, P D Forsyth, A C Rawstron, et al.
British Journal of Urology|May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activationJ K Joffe, R E Banks, M A Forbes, et al.
Pageof 32